Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB1 | P16118 | 12/20 | 0.72 |
| ▸ | PFKFB2 | O60825 | 11/20 | 0.72 |
| ▸ | PFKFB3 | Q16875 | 11/20 | 0.72 |
| ▸ | AS3MT | Q9HBK9 | 9/20 | 0.72 |
| ▸ | NSD2 | O96028 | 6/20 | 0.72 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5858444 | 1.00 | PFKFB1 (0.72) | PFKFB1PFKFB2PFKFB3AS3MTNSD2 | |
| SCHEMBL5857144 | 0.84 | PFKFB1 (1.00) | PFKFB1PFKFB2PFKFB3AS3MTNSD2 | |
| SCHEMBL5857150 | 0.84 | PFKFB1 (1.00) | PFKFB1PFKFB2PFKFB3AS3MTNSD2 | |
| SCHEMBL5857186 | 0.82 | PFKFB1 (0.78) | PFKFB1PFKFB2PFKFB3AS3MTNSD2 | |
| SCHEMBL5857191 | 0.82 | PFKFB1 (0.78) | PFKFB1PFKFB2PFKFB3AS3MTNSD2 | |
| SCHEMBL5859792 | 0.82 | PFKFB1 (0.69) | PFKFB1PFKFB2PFKFB3AS3MTNSD2 | |
| SCHEMBL5857310 | 0.81 | PFKFB1 (0.52) | PFKFB1PFKFB2PFKFB3AS3MTNSD2 | |
| SCHEMBL5857223 | 0.81 | PFKFB1 (0.79) | PFKFB1PFKFB2PFKFB3AS3MTNSD2 | |
| SCHEMBL5858621 | 0.81 | PFKFB1 (0.79) | PFKFB1PFKFB2PFKFB3AS3MTNSD2 | |
| SCHEMBL5857229 | 0.81 | PFKFB1 (0.79) | PFKFB1PFKFB2PFKFB3AS3MTNSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030123-B2 | Indole derivatives with vascular damaging activity | ASTRAZENECA AB (SE) | 2006-04-18 | — | — | US | disclosed |
| US-20030216356-A1 | Indole derivatives with vascular damaging activity | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
| EP-1289952-A1 | INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY | AstraZeneca AB (SE) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001092224-A1 | INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY | ASTRAZENECA AB (SE) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216356-A1 | Indole derivatives with vascular damaging activity | IDO1, IDO2, VEGFA | PFKFB1 3485/4885PFKFB2 3883/4885PFKFB3 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.